Brain Sciences,
Год журнала:
2025,
Номер
15(1), С. 79 - 79
Опубликована: Янв. 16, 2025
Advanced
magnetic
resonance
imaging
(MRI)
techniques
are
transforming
the
study
of
movement
disorders
by
providing
valuable
insights
into
disease
mechanisms.
This
narrative
review
presents
a
comprehensive
overview
their
applications
in
this
field,
offering
an
updated
perspective
on
potential
for
early
diagnosis,
monitoring,
and
therapeutic
evaluation.
Emerging
MRI
modalities
such
as
neuromelanin-sensitive
imaging,
diffusion-weighted
magnetization
transfer
relaxometry
provide
sensitive
biomarkers
that
can
detect
microstructural
degeneration,
iron
deposition,
connectivity
disruptions
key
regions
like
substantia
nigra.
These
enable
earlier
more
accurate
differentiation
disorders,
including
Parkinson's
disease,
progressive
supranuclear
palsy,
multiple
system
atrophy,
corticobasal
Lewy
body
frontotemporal
dementia,
Huntington's
dystonia.
Furthermore,
provides
objective
metrics
tracking
progression
assessing
efficacy,
making
it
indispensable
tool
clinical
trials.
Despite
these
advances,
absence
standardized
protocols
limits
integration
routine
practice.
Addressing
gap
incorporating
systematically
could
bring
field
closer
to
leveraging
advanced
personalized
treatment
strategies,
ultimately
improving
outcomes
individuals
with
disorders.
Journal of Neural Transmission,
Год журнала:
2022,
Номер
129(5-6), С. 505 - 520
Опубликована: Май 9, 2022
Abstract
Iron
has
a
long
and
storied
history
in
Parkinson
disease
related
disorders.
This
essential
micronutrient
is
critical
for
normal
brain
function,
but
abnormal
iron
accumulation
been
associated
with
extrapyramidal
century.
Precisely
why,
how,
when
implicated
neuronal
death
remains
the
subject
of
investigation.
In
this
article,
we
review
movement
disorders,
from
first
observations
early
twentieth
century
to
recent
efforts
that
view
as
novel
therapeutic
target
diagnostic
indicator.
Chemistry & Biodiversity,
Год журнала:
2024,
Номер
21(8)
Опубликована: Май 31, 2024
Parkinson's
disease
(PD)
is
a
neurodegenerative
condition
characterized
by
both
motor
and
non-motor
symptoms.
Although
PD
commonly
associated
with
decline
of
dopaminergic
neurons
in
the
substantia
nigra,
other
diagnostic
criteria
biomarkers
also
exist.
In
search
for
novel
therapeutic
agents,
chromene
pyran
derivatives
have
shown
potential
due
to
their
diverse
pharmacological
activities.
This
study
utilizes
comprehensive
computational
approach
investigate
viability
chromene/pyran
compounds
as
treatments
PD.
The
drug-likeness
characteristics
these
molecules
were
analyzed
using
ADMET
(Absorption,
Distribution,
Metabolism,
Excretion,
Toxicity)
studies.
Molecular
docking
was
performed
against
PDB
ID:
2V5Z.
best
three
chosen
compound
7,
24,
67
binding
energy
-6.7,
-8.6,
-10.9
kcal/mol.
Molecules
demonstrating
positive
blood-brain
barrier
permeability,
good
solubility,
favorable
affinity
further
evaluated
Density
Functional
Theory
(DFT)
calculations
Dynamics
(MD)
simulations
assess
electronic
structure
stability.
DFT
indicated
that
molecule
82
has
dipole
moment
15.70
D.
RMSD
RMSF
results
confirmed
stability
complexes
over
100
ns
simulation,
maximum
3
hydrogen
bonds
formed.
Brain Sciences,
Год журнала:
2025,
Номер
15(1), С. 79 - 79
Опубликована: Янв. 16, 2025
Advanced
magnetic
resonance
imaging
(MRI)
techniques
are
transforming
the
study
of
movement
disorders
by
providing
valuable
insights
into
disease
mechanisms.
This
narrative
review
presents
a
comprehensive
overview
their
applications
in
this
field,
offering
an
updated
perspective
on
potential
for
early
diagnosis,
monitoring,
and
therapeutic
evaluation.
Emerging
MRI
modalities
such
as
neuromelanin-sensitive
imaging,
diffusion-weighted
magnetization
transfer
relaxometry
provide
sensitive
biomarkers
that
can
detect
microstructural
degeneration,
iron
deposition,
connectivity
disruptions
key
regions
like
substantia
nigra.
These
enable
earlier
more
accurate
differentiation
disorders,
including
Parkinson's
disease,
progressive
supranuclear
palsy,
multiple
system
atrophy,
corticobasal
Lewy
body
frontotemporal
dementia,
Huntington's
dystonia.
Furthermore,
provides
objective
metrics
tracking
progression
assessing
efficacy,
making
it
indispensable
tool
clinical
trials.
Despite
these
advances,
absence
standardized
protocols
limits
integration
routine
practice.
Addressing
gap
incorporating
systematically
could
bring
field
closer
to
leveraging
advanced
personalized
treatment
strategies,
ultimately
improving
outcomes
individuals
with
disorders.
